Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov;33(11):1750-1759.
doi: 10.1002/mds.110. Epub 2018 Sep 14.

Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests

Affiliations
Review

Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests

Jeroen Hoogland et al. Mov Disord. 2018 Nov.

Abstract

Background: Numerous neuropsychological tests and test versions are used in Parkinson's disease research, but their relative capacity to detect mild cognitive deficits and their comparability across studies are unknown. The objective of this study was to identify neuropsychological tests that consistently detect cognitive decline in PD across studies.

Methods: Data from 30 normed neuropsychological tests across 20 international studies in up to 2908 nondemented PD patients were analyzed. A subset of 17 tests was administered to up to 1247 healthy controls. A 2-step meta-analytic approach using standardized scores compared performance in PD with normative data.

Results: Pooled estimates of the differences between PD and site-specific healthy controls identified significant cognitive deficits in PD patients on 14 test scores across 5 commonly assessed cognitive domains (attention or working memory, executive, language, memory, and visuospatial abilities), but healthy control performance was statistically above average on 7 of these tests. Analyses based on published norms only, as opposed to direct assessment of healthy controls, showed high between-study variability that could not be accounted for and led to inconclusive results.

Conclusions: Normed neuropsychological tests across multiple cognitive domains consistently detect cognitive deficits in PD when compared with site-specific healthy control performance, but relative PD performance was significantly affected by the inclusion and type of healthy controls versus the use of published norms only. Additional research is needed to identify a cognitive battery that can be administered in multisite international studies and that is sensitive to cognitive decline, responsive to therapeutic interventions, and superior to individual cognitive tests. © 2018 International Parkinson and Movement Disorder Society.

Keywords: MCI; Parkinson disease; cognition; mild cognitive impairment; neuropsychological.

PubMed Disclaimer

Conflict of interest statement

Relevant conflicts of interest/financial disclosures: .

Figures

FIG. 1.
FIG. 1.
Flowchart.
FIG. 2.
FIG. 2.
Pooled PD results per subtest in all participants (analysis A). A star behind the numerical estimates indicates that the lower bound of the heterogeneity index was above 50% (ie, at least half the variability in the final estimates was a result of between-study variability).
FIG. 3.
FIG. 3.
Pooled PD versus HC results per subtest (analysis B). A star behind the numerical estimates indicates that the lower bound of the heterogeneity index was above 50%.

References

    1. Aarsland D, Andersen K, Larsen J, Lolk A, Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387–392. - PubMed
    1. Litvan I, Aarsland D, Adler C, et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord 2011;26:1814–1824. - PMC - PubMed
    1. Hely M, Reid W, Adena M, Halliday G, Morris J. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837–844. - PubMed
    1. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004;351: 2509–2518. - PubMed
    1. Dubois B, Tollefson G, Katzenschlager R, et al. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 2012;27:1230–1238. - PubMed